Preventing HIV-1 Infection, Methods and Products: Theta-defensins in Mammalian Cells
A natural and endogenous mechanism to prevent viruses such as HIV-1 from infecting mammalian cells Minimal cytotoxicity in vitro
This invention can be used for the development of oral and topical microbicides such as ointments and creams to protect against HIV-1 infections.
Nearly 33 million people are infected with HIV worldwide, and despite extensive efforts there are no effective vaccines against HIV transmission. Identifying drugs that can inhibit HIV infection is essential for preventing spread of the disease. Theta-defensins, such as retrocyclins, are antimicrobial peptides that can inhibit HIV-1 entry into human cells. While these peptides are produced in old world monkeys and orangutans, they are not expressed in humans due to a premature stop codon. UCF researchers have developed a method to induce human cells to produce functional theta-defensins such as retrocyclins. The ability to restore expression of retrocyclins in human cells could provide a new mechanism to prevent HIV-1 infection.
Patent Number: US20110190385A1
Application Number: US2010699389A
Inventor: Cole, Alexander M.
Priority Date: 3 Feb 2010
Priority Number: US20110190385A1
Application Date: 3 Feb 2010
Publication Date: 4 Aug 2011
IPC Current: A61K00317088 | A61K003170 | A61P003118 | C12N000510 | C12N001574
US Class: 514044R | 4353201 | 435366 | 514042
Title: Methods and Products for Reawakening Retrocyclins
Usefulness: Methods and Products for Reawakening Retrocyclins
Summary: The method (M1) is useful for inducing expression of retrocyclin polypeptide in host cell. The method (M2) is useful for reducing virus entry into host cell of mammalian subject. The pharmaceutical composition is useful for inhibiting entry of HIV-1 cell (all claimed).
Novelty: Inducing expression of retrocyclin polypeptide in host cell, by introducing delivery vector containing polynucleotide encoding retrocyclin polypeptide into host cell
生物医学
生物工程
美国
